N-Acetylcysteine Improves Liver Function in Patients with Non-Alcoholic Fatty Liver Disease

Dalila Gargouri; Jamel Kharrat; Abdeljabbar Ghorbel; Asma Ouakaa-Kchaou

Hepatitis Monthly

Official Journal of Research Center for Gastroenterology and Liver Diseases

Current Issue All Issues In Press Articles Search Accepted Manuscripts

Journal Information Boards and committees Indexing and Listing Sources Journal Metrics Publication Ethics and Malpractice Statement Reviewer and AE Registration Form Support Contact Us Open Peer Review (OPR)

APC

Authors Guide Submit Manuscript

N-Acetylcysteine Improves Liver Function in Patients with Non-Alcoholic Fatty Liver Disease

Author(s):

Dalila Gargouri,

Jamel Kharrat,

Abdeljabbar Ghorbel,

Asma Ouakaa-Kchaou^1,*

1Department of Gastroenterology and Hepatology, Habib Thameur Hospital, Tunis, Tunisia

Hepatitis Monthly:Vol. 10, issue 4; 12-16

Published online:Mar 31, 2010

Article type:Research Article

Received:Jul 26, 2009

Accepted:Jan 13, 2010

How to Cite:Gargouri D, Kharrat J, Ghorbel A, Ouakaa-Kchaou A. N-Acetylcysteine Improves Liver Function in Patients with Non-Alcoholic Fatty Liver Disease.Hepat Mon.2010;10(4):12-16.

Abstract

Background and Aims: Non-alcoholic fatty liver change is a common disease of the liver in which oxidative stress plays a basic role. Studies are largely focused on protecting the liver by means of anti-oxidative material. The aim of this study is to evaluate the role of N- acetylcysteine in the process of liver injury.

Methods: Thirty patients with non-alcoholic fatty liver steatosis were randomly selected to receive either N-acetylcysteine or vitamin C. Liver function tests (alanine aminotransfrase, aspartate aminotransfrase and alkaline phosphatase) were measured as well as the grade of steatosis, the pattern of its echogenicity, the span of the liver and the spleen and the portal vein diameter before the intervention. Patients were followed up using the same method of evaluation repeated in the first, second and third months.

Results: The mean age (SD) was 40.1(12.4) in patients receiving NAC and 46(10.4) years in patients receiving vitamin C (P = 0.137). NAC resulted in a significant decrease of serum alanine aminotransfrase after three months, compared to vitamin C. This effect was independent of the grade of steatosis in the initial diagnosis. NAC was able to significantly decrease the span of the spleen.

Conclusions: N-acetylcysteine can improve liver function in patients with non-alcoholic fatty liver disease. Better results may be achievable in a longer follow up.

Keywords

Non-alcoholic Fatty Liver Disease

N-acetylcysteine

Therapy

Fulltext

Full text is available in PDF

comments